{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T01:51:01Z","timestamp":1783993861983,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/T008709\/1"],"award-info":[{"award-number":["BB\/T008709\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/T008709\/1"],"award-info":[{"award-number":["BB\/T008709\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W006774\/1"],"award-info":[{"award-number":["MR\/W006774\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W006774\/1"],"award-info":[{"award-number":["MR\/W006774\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT\/204870\/Z\/16\/Z"],"award-info":[{"award-number":["WT\/204870\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT\/204870\/Z\/16\/Z"],"award-info":[{"award-number":["WT\/204870\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT\/204870\/Z\/16\/Z"],"award-info":[{"award-number":["WT\/204870\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000291","name":"Kidney Research UK","doi-asserted-by":"publisher","award":["RP_008_20231101"],"award-info":[{"award-number":["RP_008_20231101"]}],"id":[{"id":"10.13039\/501100000291","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vaccination against human cytomegalovirus (HCMV) to protect transplant recipients and prevent congenital infection remains highest priority. Follow-up analyses of a vaccine directed against the fusion protein glycoprotein B (gB\/MF59) identified a vaccine-specific response (AD-6) that correlated with protection. Subsequently, it was demonstrated that AD-6 antibodies are anti-viral by preventing cell-associated spread. Here we now demonstrate AD-6 antibodies limit HCMV reactivation \u2013 an event critical for pathogenesis via hematogenic spread in vivo. To better understand the AD-6 immunogen, we use structural homology to identify putative AD-6 regions in related herpesviruses and show, despite limited sequence similarity, they share key physico-chemical properties. Of note was that AD-6 mapped to a region under high molecular frustration within gB \u2013 arguing AD-6 antibodies inhibit gB function by targeting activity dependent on conserved conformational changes. Consistent with structural conformation being crucial, we observe that both rabbit and human HCMV AD-6 antibodies recognise other herpesvirus AD-6s and that AD-6 antibodies are potently antiviral against HSV-1. Thus, a combinatorial in silico, biochemical and immunological approach reveals conformational epitopes within AD-6 are critical components of the gB\/MF59 vaccine, represent crucial conserved elements of AD-6 in gB structure and function which makes it an attractive target of multiple herpesviruses.<\/jats:p>","DOI":"10.1038\/s41541-025-01315-6","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:00:52Z","timestamp":1764936052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cross-herpesvirus immunity of the cytomegalovirus gB\/MF59 vaccine response"],"prefix":"10.1038","volume":"10","author":[{"given":"A.","family":"Lankina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hargreaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. T.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kropff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. D.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. B.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"1315_CR1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","volume":"19","author":"P Griffiths","year":"2021","unstructured":"Griffiths, P. & Reeves, M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat. Rev. Microbiol. 19, 759\u2013773 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"1315_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1473-3099(12)70197-4","volume":"12","author":"PD Griffiths","year":"2012","unstructured":"Griffiths, P. D. Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infect. Dis. 12, 790\u2013798 (2012).","journal-title":"Lancet Infect. Dis."},{"key":"1315_CR3","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1182\/blood-2002-10-3263","volume":"102","author":"P Ljungman","year":"2003","unstructured":"Ljungman, P. et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 102, 4255\u20134260 (2003).","journal-title":"Blood"},{"key":"1315_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1128\/CMR.00062-12","volume":"26","author":"S Manicklal","year":"2013","unstructured":"Manicklal, S., Emery, V. C., Lazzarotto, T., Boppana, S. B. & Gupta, R. K. The \u201csilent\u201d global burden of congenital cytomegalovirus. Clin. Microbiol. Rev. 26, 86\u2013102 (2013).","journal-title":"Clin. Microbiol. Rev."},{"key":"1315_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/00006454-200006000-00003","volume":"19","author":"DE Noyola","year":"2000","unstructured":"Noyola, D. E. et al. Cytomegalovirus urinary excretion and long term outcome in children with congenital cytomegalovirus infection. Congenital CMV Longitudinal Study Group. Pediatr. Infect. Dis. J. 19, 505\u2013510 (2000).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"1315_CR6","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1093\/infdis\/jiz428","volume":"221","author":"CS Nelson","year":"2020","unstructured":"Nelson, C. S. et al. Immune correlates of protection against human cytomegalovirus acquisition, replication, and disease. J. Infect. Dis. 221, S45\u2013S59 (2020).","journal-title":"J. Infect. Dis."},{"key":"1315_CR7","doi-asserted-by":"publisher","unstructured":"Permar, S. R., Schleiss, M. R. & Plotkin, S. A. A vaccine against cytomegalovirus: how close are we? J. Clin. Investig. 135, https:\/\/doi.org\/10.1172\/JCI182317 (2025).","DOI":"10.1172\/JCI182317"},{"key":"1315_CR8","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1128\/JVI.01251-08","volume":"83","author":"MK Isaacson","year":"2009","unstructured":"Isaacson, M. K. & Compton, T. Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J. Virol. 83, 3891\u20133903 (2009).","journal-title":"J. Virol."},{"key":"1315_CR9","doi-asserted-by":"publisher","first-page":"e00332","DOI":"10.1128\/mBio.00332-13","volume":"4","author":"PT Wille","year":"2013","unstructured":"Wille, P. T., Wisner, T. W., Ryckman, B. & Johnson, D. C. Human cytomegalovirus (HCMV) glycoprotein gB promotes virus entry in trans acting as the viral fusion protein rather than as a receptor-binding protein. mBio 4, e00332\u201300313 (2013).","journal-title":"mBio"},{"key":"1315_CR10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","volume":"34","author":"DI Bernstein","year":"2016","unstructured":"Bernstein, D. I. et al. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial. Vaccine 34, 313\u2013319 (2016).","journal-title":"Vaccine"},{"key":"1315_CR11","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","volume":"377","author":"PD Griffiths","year":"2011","unstructured":"Griffiths, P. D. et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377, 1256\u20131263 (2011).","journal-title":"Lancet"},{"key":"1315_CR12","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","volume":"360","author":"RF Pass","year":"2009","unstructured":"Pass, R. F. et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360, 1191\u20131199 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1315_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36683-x","volume":"14","author":"AC Gomes","year":"2023","unstructured":"Gomes, A. C. et al. The cytomegalovirus gB\/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread. Nat. Commun. 14, 1041 (2023).","journal-title":"Nat. Commun."},{"key":"1315_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/rmv.1862","volume":"26","author":"L Dupont","year":"2016","unstructured":"Dupont, L. & Reeves, M. B. Cytomegalovirus latency and reactivation: recent insights into an age old problem. Rev. Med. Virol. 26, 75\u201389 (2016).","journal-title":"Rev. Med. Virol."},{"key":"1315_CR15","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/jmv.21176","volume":"80","author":"N Kamar","year":"2008","unstructured":"Kamar, N. et al. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients. J. Med. Virol. 80, 1012\u20131017 (2008).","journal-title":"J. Med. Virol."},{"key":"1315_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1128\/jvi.67.2.703-710.1993","volume":"67","author":"M Ohlin","year":"1993","unstructured":"Ohlin, M., Sundqvist, V. A., Mach, M., Wahren, B. & Borrebaeck, C. A. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58\/116 (gB), as determined with human monoclonal antibodies. J. Virol. 67, 703\u2013710 (1993).","journal-title":"J. Virol."},{"key":"1315_CR17","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.1073\/pnas.1800224115","volume":"115","author":"I Baraniak","year":"2018","unstructured":"Baraniak, I. et al. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies. Proc. Natl. Acad. Sci. USA 115, 6273\u20136278 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1315_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.virol.2019.01.005","volume":"529","author":"CM Zmasek","year":"2019","unstructured":"Zmasek, C. M., Knipe, D. M., Pellett, P. E. & Scheuermann, R. H. Classification of human Herpesviridae proteins using Domain-architecture Aware Inference of Orthologs (DAIO). Virology 529, 29\u201342 (2019).","journal-title":"Virology"},{"key":"1315_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.sbi.2009.02.012","volume":"19","author":"M Backovic","year":"2009","unstructured":"Backovic, M. & Jardetzky, T. S. Class III viral membrane fusion proteins. Curr. Opin. Struct. Biol. 19, 189\u2013196 (2009).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"1315_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.virol.2012.09.024","volume":"435","author":"S Sharma","year":"2013","unstructured":"Sharma, S., Wisner, T. W., Johnson, D. C. & Heldwein, E. E. HCMV gB shares structural and functional properties with gB proteins from other herpesviruses. Virology 435, 239\u2013249 (2013).","journal-title":"Virology"},{"key":"1315_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.virusres.2006.01.002","volume":"117","author":"DJ McGeoch","year":"2006","unstructured":"McGeoch, D. J., Rixon, F. J. & Davison, A. J. Topics in herpesvirus genomics and evolution. Virus Res. 117, 90\u2013104 (2006).","journal-title":"Virus Res."},{"key":"1315_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1073\/pnas.37.4.205","volume":"37","author":"L Pauling","year":"1951","unstructured":"Pauling, L., Corey, R. B. & Branson, H. R. The structure of proteins; two hydrogen-bonded helical configurations of the polypeptide chain. Proc. Natl. Acad. Sci. USA 37, 205\u2013211 (1951).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1315_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1006\/scbi.1998.0115","volume":"9","author":"JU Jung","year":"1999","unstructured":"Jung, J. U., Choi, J. K., Ensser, A. & Biesinger, B. Herpesvirus saimiri as a model for gammaherpesvirus oncogenesis. Semin. Cancer Biol. 9, 231\u2013239 (1999).","journal-title":"Semin. Cancer Biol."},{"key":"1315_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.sbi.2017.09.006","volume":"48","author":"DU Ferreiro","year":"2018","unstructured":"Ferreiro, D. U., Komives, E. A. & Wolynes, P. G. Frustration, function and folding. Curr. Opin. Struct. Biol. 48, 68\u201373 (2018).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"1315_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.tim.2023.07.003","volume":"32","author":"R Twarock","year":"2024","unstructured":"Twarock, R., Towers, G. J. & Stockley, P. G. Molecular frustration: a hypothesis for regulation of viral infections. Trends Microbiol. 32, 17\u201326 (2024).","journal-title":"Trends Microbiol."},{"key":"1315_CR26","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1016\/j.vaccine.2019.04.096","volume":"37","author":"V Kesherwani","year":"2019","unstructured":"Kesherwani, V. & Tarang, S. An immunoinformatic approach to universal therapeutic vaccine design against BK virus. Vaccine 37, 3457\u20133463 (2019).","journal-title":"Vaccine"},{"key":"1315_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/cmdc.202000411","volume":"16","author":"FJ Luque","year":"2021","unstructured":"Luque, F. J. & Camarasa, M. J. HIV-1 Envelope Spike MPER: from a vaccine target to a new druggable pocket for novel and effective fusion inhibitors. ChemMedChem 16, 105\u2013107 (2021).","journal-title":"ChemMedChem"},{"key":"1315_CR28","doi-asserted-by":"publisher","first-page":"8333","DOI":"10.1128\/JVI.78.15.8333-8341.2004","volume":"78","author":"M Lopper","year":"2004","unstructured":"Lopper, M. & Compton, T. Coiled-coil domains in glycoproteins B and H are involved in human cytomegalovirus membrane fusion. J. Virol. 78, 8333\u20138341 (2004).","journal-title":"J. Virol."},{"key":"1315_CR29","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1021\/bi00462a002","volume":"29","author":"DS Lyles","year":"1990","unstructured":"Lyles, D. S., Varela, V. A. & Parce, J. W. Dynamic nature of the quaternary structure of the vesicular stomatitis virus envelope glycoprotein. Biochemistry 29, 2442\u20132449 (1990).","journal-title":"Biochemistry"},{"key":"1315_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1083\/jcb.201006116","volume":"191","author":"S Libersou","year":"2010","unstructured":"Libersou, S. et al. Distinct structural rearrangements of the VSV glycoprotein drive membrane fusion. J. Cell Biol. 191, 199\u2013210 (2010).","journal-title":"J. Cell Biol."},{"key":"1315_CR31","doi-asserted-by":"publisher","first-page":"11686","DOI":"10.1128\/JVI.01349-14","volume":"88","author":"J Chen","year":"2014","unstructured":"Chen, J., Zhang, X., Jardetzky, T. S. & Longnecker, R. The Epstein-Barr virus (EBV) glycoprotein B cytoplasmic C-terminal tail domain regulates the energy requirement for EBV-induced membrane fusion. J. Virol. 88, 11686\u201311695 (2014).","journal-title":"J. Virol."},{"key":"1315_CR32","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion. Sci. Adv. 7, https:\/\/doi.org\/10.1126\/sciadv.abf3178 (2021).","DOI":"10.1126\/sciadv.abf3178"},{"key":"1315_CR33","doi-asserted-by":"publisher","unstructured":"Lankina, A. et al. Developing a vaccine against human cytomegalovirus: identifying and targeting HCMV\u2019s immunological Achilles\u2019 heel. Vaccines 13, https:\/\/doi.org\/10.3390\/vaccines13050435 (2025).","DOI":"10.3390\/vaccines13050435"},{"key":"1315_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00792-x","volume":"9","author":"S Musunuri","year":"2024","unstructured":"Musunuri, S., Weidenbacher, P. A. B. & Kim, P. S. Bringing immunofocusing into focus. npj Vaccines 9, 11 (2024).","journal-title":"npj Vaccines"},{"key":"1315_CR35","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.3390\/v7092856","volume":"7","author":"GK Lewis","year":"2015","unstructured":"Lewis, G. K., Finzi, A., DeVico, A. L. & Pazgier, M. Conformational masking and receptor-dependent unmasking of highly conserved Env epitopes recognized by non-neutralizing antibodies that mediate potent ADCC against HIV-1. Viruses 7, 5115\u20135132 (2015).","journal-title":"Viruses"},{"key":"1315_CR36","doi-asserted-by":"publisher","first-page":"11837","DOI":"10.1128\/JVI.01623-08","volume":"82","author":"AL Vanarsdall","year":"2008","unstructured":"Vanarsdall, A. L., Ryckman, B. J., Chase, M. C. & Johnson, D. C. Human cytomegalovirus glycoproteins gB and gH\/gL mediate epithelial cell-cell fusion when expressed either in cis or in trans. J. Virol. 82, 11837\u201311850 (2008).","journal-title":"J. Virol."},{"key":"1315_CR37","doi-asserted-by":"publisher","first-page":"e0003525","DOI":"10.1128\/jvi.00035-25","volume":"99","author":"EP Schultz","year":"2025","unstructured":"Schultz, E. P. et al. Human cytomegalovirus gH\/gL\/gO binding to PDGFRalpha provides a regulatory signal activating the fusion protein gB that can be blocked by neutralizing antibodies. J. Virol. 99, e0003525 (2025).","journal-title":"J. Virol."},{"key":"1315_CR38","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1073\/pnas.1800177115","volume":"115","author":"CS Nelson","year":"2018","unstructured":"Nelson, C. S. et al. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc. Natl. Acad. Sci. USA 115, 6267\u20136272 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1315_CR39","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1099\/0022-1317-80-8-2183","volume":"80","author":"A Speckner","year":"1999","unstructured":"Speckner, A., Glykofrydes, D., Ohlin, M. & Mach, M. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J. Gen. Virol. 80, 2183\u20132191 (1999).","journal-title":"J. Gen. Virol."},{"key":"1315_CR40","doi-asserted-by":"publisher","unstructured":"Ebel, H., Benecke, T. & Vollmer, B. Stabilisation of viral membrane fusion proteins in prefusion conformation by structure-based design for structure determination and vaccine development. Viruses 14, https:\/\/doi.org\/10.3390\/v14081816 (2022).","DOI":"10.3390\/v14081816"},{"key":"1315_CR41","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1086\/514145","volume":"176","author":"AV Cope","year":"1997","unstructured":"Cope, A. V. et al. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J. Infect. Dis. 176, 1484\u20131490 (1997).","journal-title":"J. Infect. Dis."},{"key":"1315_CR42","first-page":"CD005133","volume":"2013","author":"DS Owers","year":"2013","unstructured":"Owers, D. S., Webster, A. C., Strippoli, G. F., Kable, K. & Hodson, E. M. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev. 2013, CD005133 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1315_CR43","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/S0140-6736(00)02350-3","volume":"355","author":"VC Emery","year":"2000","unstructured":"Emery, V. C. et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355, 2032\u20132036 (2000).","journal-title":"Lancet"},{"key":"1315_CR44","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1128\/JVI.01539-13","volume":"87","author":"MB Reeves","year":"2013","unstructured":"Reeves, M. B. & Sinclair, J. H. Circulating dendritic cells isolated from healthy seropositive donors are sites of human cytomegalovirus reactivation in vivo. J. Virol. 87, 10660\u201310667 (2013).","journal-title":"J. Virol."},{"key":"1315_CR45","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/s41564-025-02025-4","volume":"10","author":"MJ Norris","year":"2025","unstructured":"Norris, M. J. et al. The GATE glycoprotein complex enhances human cytomegalovirus entry in endothelial cells. Nat. Microbiol. 10, 1605\u20131616 (2025).","journal-title":"Nat. Microbiol."},{"key":"1315_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-7-339","volume":"7","author":"EC Meng","year":"2006","unstructured":"Meng, E. C., Pettersen, E. F., Couch, G. S., Huang, C. C. & Ferrin, T. E. Tools for integrated sequence-structure analysis with UCSF Chimera. BMC Bioinform. 7, 339 (2006).","journal-title":"BMC Bioinform."},{"key":"1315_CR47","doi-asserted-by":"publisher","first-page":"e4792","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng, E. C. et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci. 32, e4792 (2023).","journal-title":"Protein Sci."},{"key":"1315_CR48","doi-asserted-by":"publisher","first-page":"W60","DOI":"10.1093\/nar\/gkaa443","volume":"48","author":"Z Li","year":"2020","unstructured":"Li, Z., Jaroszewski, L., Iyer, M., Sedova, M. & Godzik, A. FATCAT 2.0: towards a better understanding of the structural diversity of proteins. Nucleic Acids Res. 48, W60\u2013W64 (2020).","journal-title":"Nucleic Acids Res."},{"key":"1315_CR49","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"1315_CR50","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/molbev\/mst010","volume":"30","author":"K Katoh","year":"2013","unstructured":"Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772\u2013780 (2013).","journal-title":"Mol. Biol. Evol."},{"key":"1315_CR51","doi-asserted-by":"publisher","first-page":"W24","DOI":"10.1093\/nar\/gkx346","volume":"45","author":"MC Jespersen","year":"2017","unstructured":"Jespersen, M. C., Peters, B., Nielsen, M. & Marcatili, P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 45, W24\u2013W29 (2017).","journal-title":"Nucleic Acids Res."},{"key":"1315_CR52","doi-asserted-by":"publisher","first-page":"7563","DOI":"10.1128\/JVI.72.9.7563-7568.1998","volume":"72","author":"P Desai","year":"1998","unstructured":"Desai, P. & Person, S. Incorporation of the green fluorescent protein into the herpes simplex virus type 1 capsid. J. Virol. 72, 7563\u20137568 (1998).","journal-title":"J. Virol."},{"key":"1315_CR53","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01315-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:06:04Z","timestamp":1764939964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01315-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01315-6","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.D.G. and M.R. are co-inventors on WO Patent WO 2022\/129937A1, assigned to University College London (UCL), entitled \u2018hCMV antibody and vaccine target\u2019, that deals with a novel antigenic domain in HCMV glycoprotein B (gB). M.B.R. has led sponsored research funded by Moderna. The authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}